Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
PBMs’ use of “clawbacks” prompt lawsuits; Merck’s experimental antiviral drug prevents infection; EMA recommends Novartis’ lung-cancer combo drug
Spending for inflammatory drugs like AbbVie’s Humira and Amgen’s Enbrel rose, while hepatitis C drugs showed decline.
FDA solicits public comment to study online character space limit; Biogen’s Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to: